Stable iron oligosaccharide compound

Abstract

The invention relates to an iron oligosaccharide compound with improved stability comprising a hydrogenated oligosaccharide in stable association with ferric oxyhydroxide, the content of dimes saccharide in said hydrogenated oligosaccharide being 2.9% by weight or less, based on the total weight of the hydrogenated oligosaccharide. In further aspects is provided a process for preparing said compound as well as the use of said compound for preparation of a composition for treatment of iron deficiency anaemia.

Claims

1. A hydrogenated oligosaccharide, which hydrogenated oligosaccharide when combined with ferric oxyhydroxide is capable of forming a stable iron oligosaccharide compound, wherein said hydrogenated oligosaccharide comprises a mixture of hydrogenated dextran oligosaccharides having the following molecular weight distribution: (i) a weight average molecular weight (Mw) between 500 and 3,000 Daltons, (ii) a dimer saccharide content of 2.9% by weight or less, based on the total weight of the hydrogenated oligosaccharide, (iii) a number average molecular weight (Mn) above 500 Daltons; (iv) 90% by weight of said hydrogenated dextran oligosaccharides have molecular weights of less than 3,500 Daltons, and (v) the Mw of the 10% by weight fraction containing the hydrogenated dextran oligosaccharides having the highest molecular weights is below 4,500 Daltons.

2. An iron oligosaccharide compound comprising a hydrogenated oligosaccharide in stable association with ferric oxyhydroxide, wherein said hydrogenated oligosaccharide comprises a mixture of hydrogenated dextran oligosaccharides having the following molecular weight distribution: (i) a weight average molecular weight (Mw) between 500 and 3,000 Daltons, (ii) a number average molecular weight (Mn) above 500 Daltons; (iii) 90% by weight of said hydrogenated dextran oligosaccharides have molecular weights of less than 3,500 Daltons, and (iv) the Mw of the 10% by weight fraction containing the hydrogenated dextran oligosaccharides having the highest molecular weights is below 4,500 Daltons, (v) a dimer saccharide content of 2.9% by weight or less, based on the total weight of the hydrogenated oligosaccharide, and wherein the apparent molecular weight (M.sub.P) of the iron oligosaccharide compound is between 120,000 and 180,000 Daltons.

3. The iron oligosaccharide compound of claim 2, wherein the M.sub.P of the iron oligosaccharide compound is between 130,000 and 180,000 Daltons.

4. The iron oligosaccharide compound of claim 2, wherein the M.sub.P of the iron oligosaccharide compound is between 130,000 and 160,000 Daltons.

5. The iron oligosaccharide compound of claim 2, wherein the M.sub.P of the iron oligosaccharide compound is measured by size exclusion chromatography.

6. The iron oligosaccharide compound of claim 2, wherein said iron oligosaccharide compound is sterilized by autoclaving.

7. The iron oligosaccharide compound of claim 2, wherein the Mw of said hydrogenated oligosaccharide is 1,600 Daltons or less.

8. The iron oligosaccharide compound of claim 2, wherein the Mn of said hydrogenated oligosaccharide is 1,600 Daltons or less.

9. The iron oligosaccharide compound of claim 2, wherein 90% by weight of said hydrogenated dextran oligosaccharides have molecular weights of less than 2,700 Daltons.

10. The iron oligosaccharide compound of claim 2, wherein the Mw of the 10% by weight fraction containing the hydrogenated dextran oligosaccharides having the highest molecular weights is below 3,200 Daltons.

11. The iron oligosaccharide compound of claim 2, wherein the content of dimer saccharide in the hydrogenated oligosaccharide is 2.5% by weight or less, based on the total weight of the hydrogenated oligosaccharide.

12. The iron oligosaccharide compound of claim 2, wherein the content of dimer saccharide in the hydrogenated oligosaccharide is 2.3% by weight or less, based on the total weight of the hydrogenated oligosaccharide.

13. The iron oligosaccharide compound of claim 2, wherein the content of monomer saccharide in said hydrogenated oligosaccharide is 0.5% by weight or less, based on the total weight of the hydrogenated oligosaccharide.

14. The iron oligosaccharide compound of claim 2, wherein the amount of iron (Fe) in the iron oligosaccharide compound is more than 10% by weight and is 50% by weight or less.

15. The iron oligosaccharide compound of claim 2, further comprising the salt of an organic hydroxy acid.

16. The iron oligosaccharide compound of claim 15, wherein the organic hydroxy acid is citric acid.

17. A composition comprising the iron oligosaccharide compound of claim 2 and at least one pharmaceutically acceptable carrier.

18. The composition of claim 17, wherein said composition has an iron content of 1-20% w/v.

19. The composition of claim 17, wherein said composition has an iron content of 10% w/v.

20. The composition of claim 18, which is an injection liquid adapted for administration in a human.

21. The composition of claim 19, which is an injection liquid adapted for administration in a human.

22. The composition of claim 20, which is an aqueous liquid comprising the iron oligosaccharide compound in dissolved or dispersed form.

23. The composition of claim 21, which is an aqueous liquid comprising the iron oligosaccharide compound in dissolved or dispersed form.

24. An iron oligosaccharide compound comprising a hydrogenated oligosaccharide in stable association with ferric oxyhydroxide, wherein said hydrogenated oligosaccharide comprises a mixture of hydrogenated dextran oligosaccharides having the following molecular weight distribution: (i) a weight average molecular weight (Mw) between 500 and 1,600 Daltons, (ii) a number average molecular weight (Mn) is above 500 Daltons, (iii) 90% by weight of said hydrogenated dextran oligosaccharides have molecular weights of less than 2,700 Daltons, (iv) the Mw of the 10% by weight fraction of the hydrogenated dextran oligosaccharides having the highest molecular weights is below 3,200 Daltons, and (v) a dimer saccharide content of 2.3% by weight or less, based on the total weight of the hydrogenated oligosaccharide, (vi) the content of monomer saccharide in said hydrogenated oligosaccharide is 0.5% by weight or less, based on the total weight of the hydrogenated oligosaccharide, and wherein the apparent molecular weight (M.sub.P) of the iron oligosaccharide compound is 130,000 to 160,000 Daltons.

25. The iron oligosaccharide compound of claim 24, wherein the Mw of said hydrogenated oligosaccharide is approximately 1,000 Daltons.

26. The iron oligosaccharide compound of claim 24, wherein the amount of iron (Fe) in the iron oligosaccharide compound is 25% by weight.

27. The iron oligosaccharide compound of claim 24, further comprising the salt of an organic hydroxy acid.

28. The iron oligosaccharide compound of claim 27, wherein the organic hydroxy acid is citric acid.

29. A composition comprising an injection liquid adapted for administration in a human which comprises the iron oligosaccharide compound of claim 24 in an amount of 1-20% (w/v) iron and at least one pharmaceutically acceptable carrier.

30. The composition of claim 29, which is an aqueous liquid comprising the iron oligosaccharide compound in dissolved or dispersed form.

Description

BRIEF DESCRIPTION OF THE SEVERAL VIEWS OF THE DRAWING

(1) FIG. 1 shows a plot of the t.sub.1/2 vs. the dimer content of the iron oligosaccharide products.

EXAMPLES

(2) Hydrolysis and Hydrogenation of Dextran

(3) An amount of pre-hydrolysed dextran collected as permeate from a membrane having a cut-off value <5,000 Daltons is further hydrolysed at pH 1.5 at a temperature of 95 C.

(4) The hydrolysis is monitored using gel permeation chromatography (GPC) and is terminated by cooling, when the molecular weight of the material being hydrolysed is estimated to have achieved the desired value, i.e. a weight average molecular weight of 700-1,400 Daltons.

(5) In the hydrolysis, low molecular weight dextran is produced but also glucose and iso-maltose are formed. Upon hydrolysis, the disaccharide content is at 7-8% by weight.

(6) After cooling and neutralization, the amount of monomer and dimer is reduced by membrane processes having a cut-off value of 340-800 Daltons. The concentration of monosaccharide and disaccharide in the solution is monitored by gel permeation chromatography, and fractionation goes on until a dimer concentration of 2.9% by weight or less and a monomer concentration of 0.5% by weight or less is achieved.

(7) Thereafter, the content of dextran is determined by optical rotation and the amount of reducing sugar is determined by use of Somogyi's reagent. To bring down the reducing capability below 3%, sodium borohydride is added to the solution at basic pH. The applied ratio of sodium borohydride:fractionated dextran is 1:34.7.

(8) The solution is neutralized to pH<7.0 and subsequently de-ionized. The average molecular weights and the molecular weight distribution are determined chromatographically. Chromatography reveals that the desired conditions, viz. that 90% by weight of the dextran has a molecular weight less than 2,700 Daltons and that the weight average molecular weight (Mw) of the 10% by weight fraction of the dextran having the highest molecular weight is below 3,200 Daltons, are fulfilled. The final yield of dextran after de-ionization is approximately 50% relative to the initial amount of pre-hydrolysed dextran.

Synthesis of Iron-Dextran

(9) 120 kg dextran as produced above is mixed as an 18% solution with 150 kg FeCl.sub.3, 6 H.sub.2O. To the agitated mixture, 93 kg Na.sub.2CO.sub.3 as a saturated aqueous solution is added, whereupon the pH is raised to 10.5 using 24 liters of concentrated aqueous NaOH (27% (w/v)).

(10) The mixture thus obtained is heated above 100 C. until it turns into a black or dark brown colloidal solution. After cooling, the solution is neutralized using 12 liters concentrated hydrochloric acid to obtain a pH of 5.8. After filtration the solution is purified using membrane processes until the chloride content in the solution is less than 035% calculated on basis of a solution containing 5% (w/v) iron.

(11) If the chloride content of the solution is less than desired to obtain an isotonic solution, sodium chloride is added and pH is finally adjusted to 5.6, and the solution is filtered through a 0.45 m (or alternatively a 0.2 m) membrane filter.

(12) The solution is spray dried and the iron-dextran powder is ready for marketing or for further processing.

(13) As an alternative to spray drying, the solution may be used for direct production of injection liquids having an iron content of e.g. 10% (w/v), as described above.

(14) When using the iron-dextran powder for producing injection or infusion liquids, the powder is re-dissolved in an aqueous medium, the pH is checked and, if necessary, adjusted, and the solution is filled into ampoules or vials after being sterilized by filtration. Alternatively, the sterilization can take place by autoclaving after filling into ampoules or vials.

(15) Analysis of the Stability of Iron Oligosaccharide Compounds Relative to their Content of Dimer

(16) A range of iron oligosaccharide compounds with differing contents of disaccharide were analysed with respect to their rate of hydrolysis and apparent molecular weight, both of which are indicative of the quality of the respective compounds.

(17) The rate of hydrolysis of Fe.sup.3+ from the compound of FeOOH and oligosaccharide in acidic solution (0.24 M HCl; 0.9% NaCl) is assumed to be correlated to the rate of physiological release of iron. Therefore, the rate of hydrolysis as expressed by the half-life (t.sub.1/2) is an important parameter of the investigated compounds.

(18) The hydrolysis of Fe.sup.3+ was measured by optical absorbance at 287.3 nm.

(19) Besides, it was found that the thermostability of iron oligosaccharides is a function of their apparent molecular weight (M.sub.P). Thus, such compounds are unstable to an unsatisfactory degree, if the apparent molecular weight markedly exceeds a value of 160,000 Daltons upon storage at an elevated temperature for three months as test solutions.

(20) The results are shown in Table 1.

(21) TABLE-US-00001 TABLE 1 Assessment after keeping Iron Amount of at elevated oligosaccharide dimer in temperature compound no. oligosaccharide t.sub.1/2/hours M.sub.P/Daltons for 3 months 1 0.5% 25.5 133,490 stable 2 0.75% 21.7 149,532 stable 3 0.75% 22.5 146,353 stable 4 1.6% 21.6 138,053 stable 6 1.6% 18.3 145,250 stable 7 2.0% 20.9 150,983 stable 8 2.0% 20.3 142,664 stable 9 3.0% 12.1 152,516 unstable 10 5.0% 12.2 185,433 unstable 11 8.0% 9.7 215,143 unstable

(22) As appears from Table 1, the apparent molecular weight is in a desirable range, viz. about 130 kD to about 160 kD, when the amount of dimer in the oligosaccharide is less than 3%. The same holds true for the rate of hydrolysis as expressed by the half-life. The Half-life (t.sub.1/2) is defined as the time at which the absorbance is the half of the value compared the absorbance at t=0.

(23) The results shown in Table 1 above may be arranged into two series. When the results are plotted into a diagram of t.sub.1/2 vs. the dimer content FIG. 1 appears. The two straight lines fitted into the two series show an interception at a dimer content of 3.5% by weight and t.sub.1/2 of 126 hours.